4.26
-0.06 (-1.39%)
| Penutupan Terdahulu | 4.32 |
| Buka | 4.35 |
| Jumlah Dagangan | 1,496,243 |
| Purata Dagangan (3B) | 2,078,211 |
| Modal Pasaran | 819,300,352 |
| Harga / Jualan (P/S) | 55.62 |
| Harga / Buku (P/B) | 10.57 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Mar 2026 |
| Margin Operasi (TTM) | -738.49% |
| EPS Cair (TTM) | -0.410 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 15.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.07% |
| Nisbah Semasa (MRQ) | 6.01 |
| Aliran Tunai Operasi (OCF TTM) | -58.95 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -28.88 M |
| Pulangan Atas Aset (ROA TTM) | -31.58% |
| Pulangan Atas Ekuiti (ROE TTM) | -79.02% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Arbutus Biopharma Corporation | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -3.5 |
| Purata | 0.13 |
|
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 21.89% |
| % Dimiliki oleh Institusi | 59.38% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Blackbarn Capital Partners Lp | 31 Dec 2025 | 1,850,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |